[Recommendations for inhaled nitric oxide treatment in the newborn diseases].
The recommendations in this document highlight current indications for inhaled nitric oxide (iNO) treatment in the newborn by clearly differentiating between those that are supported by scientific evidence and those for which evidence is still lacking. However, the use of this treatment in preterm infants and in those with congenital heart disease has not yet been scientifically approved. We discuss the methodology, dosage and adverse effects of iNO administration, as well as the reasons for its ineffectiveness.